Will you offer Ibrutinib and Rituximab for untreated patients with CLL without a 17p deletion?
Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Rituximab/Ibrutinib?
Community PollStarted
How do you treat a <70yo patient with CLL without a 17p del in the first line setting?
119 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Christie NHS Foundation Trust
Answered on
The ECOG 1912 study presented at ASH this week showed better OS and PFS in younger patients with ibrutinib, which was great news. I used to use FCR in these patients as it was said to have a higher rate of MRD but potentially dangerous myelo- and immunotoxicity and of course there's concerning issue...
Join for free or sign in to see the full answer